All News

This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.

Naloxone hydrochloride (Amneal Pharmaceuticals Inc) is the generic equivalent to OTC Narcan (Emergent).

Advances, challenges, and promising innovations emerge.

A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.

Tune into this episode of “Public Health Matters” to learn about Dr. Pauline K. Long and her entrepreneurship journey, as well as how she creates meaningful impacts on patients in marginalized communities and within public health.

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.

Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

Multiple state and federal laws since the COVID-19 pandemic highlight the growing role of technicians

Carefully checking every piece of information and proofreading for accuracy is crucial to ensure patient safety

Pharmacists play a key role in psychiatric medication overdose situations

Successful integration demands overcoming various hurdles.

Laura Gillespie, PharmD, discusses some of the financial benefits of having a pharmacist focused on antimicrobial stewardship efforts in a health system.

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can influence migraines.

With migraine as a leading disability for those under the age of 50, treatment options for migraine should be personalized to the patient and their needs.

Frexalimab demonstrated a favorable tolerability profile after approximately 1 year of treatment for individuals with relapsing disease.

Ofatumumab (Kesimpta; Novartis) demonstrated a sustained efficacy as a first-line, continuous treatment for patients recently diagnosed and treatment-naïve with relapsing multiple sclerosis.

PAPs in this model can significantly reduce OOP costs regardless of the pharmacy setting.

Conversations and counseling points should be tailored to patients’ individual needs and treatment goals

Laura Gillespie, PharmD, discusses the impact of pharmacist-led initiatives on health care–associated C diff rates for health care systems.

Investigators found that younger age groups had significantly longer lengths of stay compared to those older than 75 years.

The trial will compared the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and pembrolizumab for metastatic non-squamous non-small cell lung cancer.

Optical glucose sensing techniques have been reported, but they require complex optical instrumentations found in laboratories, so feasibility for patient use has been challenging.